Tertiary Lymphoid Structures Related Genes Predicting Prognosis in Clear Cell Renal Cell Carcinoma: a Retrospective Cohort Study
Launched by DING-WEI YE · Mar 13, 2025
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients diagnosed with renal cell carcinoma
- Exclusion Criteria:
- • incomplete medical records, inadequate follow-up information, and confirmed non-prostatic acinar adenocarcinoma
About Ding Wei Ye
Ding-Wei Ye is a distinguished clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a focus on rigorous scientific methodologies and ethical standards, the organization collaborates with leading researchers and healthcare professionals to conduct high-quality clinical trials across various therapeutic areas. Ding-Wei Ye emphasizes transparency, patient safety, and regulatory compliance, ensuring that each study contributes valuable insights to the medical community. Their dedication to fostering partnerships and driving advancements in healthcare positions them as a key player in the evolution of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, , China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported